Hepatitis B surface antigen levels: Association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients

Hepatology International

Volumn 7, Issue 1, 2013, Pages 88-97

  Marcellin, Patrick ^a   Bonino, Ferruccio ^b   Yurdaydin, Cihan ^c   Hadziyannis, Stephanos ^d   Moucari, Rami ^a   Kapprell, Hans Peter ^e   Rothe, Vivien ^f   Popescu, Matei ^g   Brunetto, Maurizia R ^b  

^a CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c ANKARA UNIVERSITY   (Turkey)

^d HENRY DUNANT HOSPITAL   (Greece)

^e ABBOTT GMBH AND CO KG   (Germany)

^f IST GmbH   (Germany)

^g F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Chronic hepatitis B; HBsAg clearance; HBV DNA suppression; Long term response; Prediction

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; VIRUS DNA;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL CLEARANCE;

EID: 84875279880     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-012-9343-x     Document Type: Article

References (26)

1. AS Lok BJ McMahon 2009 Chronic hepatitis B: update 2009 Hepatology 50 1 36
2. European Association for the Study of the Liver 2009 EASL clinical practice guidelines: management of chronic hepatitis B J Hepatol 50 227 242 10.1016/j.jhep.2008.10.001
3. G Fattovich F Bortolotti F Donato 2008 Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors J Hepatol 48 335 352 18096267 10.1016/j.jhep.2007.11.011
4. HI Yang SN Lu YF Liaw, et al. 2002 Hepatitis B e antigen and the risk of hepatocellular carcinoma N Engl J Med 347 168 174 12124405 10.1056/NEJMoa013215 1:CAS:528:DC%2BD38Xlt12jsLw%3D
5. J Simonetti L Bulkow BJ McMahon, et al. 2010 Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus Hepatology 51 1531 1537 20087968 10.1002/hep.23464
6. EK Manesis SJ Hadziyannis 2001 Interferon alfa treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B Gastroenterology 121 101 109 11438498 10.1053/gast.2001.25524 1:CAS:528:DC%2BD3MXlt1ykt7o%3D
7. P Marcellin F Bonino GK Lau, et al. 2009 Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alfa-2a Gastroenterology 136 2169 2179 19303414 10.1053/j.gastro.2009.03.006 1:CAS:528:DC%2BD1MXotVeqtbw%3D
8. Y-F Liaw C-M Chu 2009 Hepatitis B virus infection Lancet 373 582 592 19217993 10.1016/S0140-6736(09)60207-5 1:CAS:528:DC%2BD1MXhvFGltLk%3D
9. C-J Chen UJ Iloeje HI Yang 2007 Long-term outcomes in hepatitis B: the REVEAL-HBV study Clin Liver Dis 11 797 816 17981229 10.1016/j.cld.2007.08.005
10. CJ Chen HI Yang J Su, et al. 2006 Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 65 73 16391218 10.1001/jama.295.1.65 1:CAS:528:DC%2BD28XhtlKqtQ%3D%3D
11. P Lampertico E Del Ninno M Viganò, et al. 2003 Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy Hepatology 37 756 763 12668967 10.1053/jhep.2003.50148 1:CAS:528:DC%2BD3sXjt1Wltbo%3D
12. MR Brunetto F Oliveri B Coco, et al. 2002 Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long-term cohort study J Hepatol 36 263 270 11830339 10.1016/S0168-8278(01) 00266-5 1:CAS:528:DC%2BD38Xit1eis7s%3D
13. P Marcellin GK Lau F Bonino, et al. 2004 Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N Engl J Med 351 1206 1217 15371578 10.1056/NEJMoa040431 1:CAS:528:DC%2BD2cXns12rsr0%3D
14. R Moucari V Mackiewicz O Lada, et al. 2009 Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients Hepatology 49 1151 1157 19115222 10.1002/hep.22744 1:CAS:528:DC%2BD1MXkslSqu7k%3D
15. EK Manesis ES Hadziyannis OP Angelopoulou, et al. 2007 Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels Antivir Ther 12 73 82 17503750 1:CAS:528:DC%2BD2sXjs1Gnt7w%3D
16. MC Kuhns SH Kleinman AL McNamara, et al. 2004 Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy Transfusion 44 1332 1339 15318857 10.1111/j.1537-2995.2004.04055.x 1:CAS:528:DC%2BD2cXotlSkurw%3D
17. MR Brunetto F Moriconi F Bonino, et al. 2009 Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B Hepatology 49 1141 1150 19338056 10.1002/hep.22760 1:CAS:528:DC%2BD1MXkslSqu7g%3D
18. TT Chang CL Lai S Kew Yoon, et al. 2010 Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B Hepatology 51 422 430 20049753 10.1002/hep.23327 1:CAS:528:DC%2BC3cXisVGgurs%3D
19. P Marcellin EJ Heathcote M Buti, et al. 2008 Tenofovir disoproxil fumerate versus adefovir dipivoxil for chronic hepatitis B N Engl J Med 359 2442 2455 19052126 10.1056/NEJMoa0802878 1:CAS:528:DC%2BD1cXhsVCrurjL
20. T Nguyen AJ Thompson S Bowden, et al. 2010 Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia J Hepatol 52 508 513 20206400 10.1016/j.jhep.2010.01.007 1:CAS:528: DC%2BC3cXjvFKmsLY%3D
21. J Jaroszewicz B Calle Serrano K Wursthorn, et al. 2010 Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective J Hepatol 52 514 522 20207438 10.1016/j.jhep.2010.01.014 1:CAS:528:DC%2BC3cXjvFKmsLc%3D
22. F Bonino P Marcellin GK Lau, et al. 2007 Predicting response to peginterferon-alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B Gut 56 699 705 17127704 10.1136/gut.2005.089722 1:CAS:528:DC%2BD2sXlvVKlt7Y%3D
23. R Moucari M Martinot-Peignoux V Mackiewicz, et al. 2009 Influence of genotype of hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a Antivir Ther 14 1183 1188 20032548 10.3851/IMP1458 1:CAS:528:DC%2BC3cXitVyqu70%3D
24. V Rijckborst BE Hansen Y Cakaloglu, et al. 2010 Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels Hepatology 52 454 461 20683945 10.1002/hep.23722 1:CAS:528:DC%2BC3cXhtV2ju7vO
25. P Lampertico M Vigano G Di Costanzo, et al. 2010 Extended (2 years) treatment with peginterferon alfa-2a (40KD) improves sustained response rates in genotype D patients with HBeAg negative chronic hepatitis B J Hepatol 52 Suppl. 1 S45 10.1016/S0168-8278(10)60100-6
26. Brunetto MR, Marcellin P, Bonino F et al. HBsAg decline in HBeAg-negative patients treated with peginterferon alfa-2a is associated with sustained response up to 5 years post-treatment: patients with continuous HbsAg decline starting before week 24 achieve highest rates of response. Hepatology (2010) 50 Suppl 4:137A (P452)